Sanofi Pulls Obesity Drug Acomplia From EU Market
The European Medicines Agency issued a notice on Thursday asking Sanofi to stop marketing Acomplia, alleging that the risks of the drug outweigh its benefits.
The agency, responsible for evaluating products in the European Union, said that the diet drug carried an approximately doubled risk of psychiatric disorders compared with a placebo.
The results of the study will be sent to the...
To view the full article, register now.